Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Gangadhar TC, Clark JI, Karrison T, Gajewski TF. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.

View in: PubMed

collapse authors with profiles